Japanese drug firms eyeing international investments should not be put off by Daiichi Sankyo’s turbulent ownership of Ranbaxy according to an Indian delegation in Tokyo last week to seek collaborations.
Ranbaxy Laboratories is putting all of its weight behind a quality push following its admission of manufacturing adulterated drugs, and just as its parent company Daiichi Sankyo is pursuing legal action.
Two approvals in a week for drugs made at Ranbaxy’s New Jersey OHM Laboratories subsidiary have eased the generics firm’s North American regulatory woes and strengthened its position in the expanding US market.
Ranbaxy has claimed that a pharmaceutical company is making a
concerted effort to depress the company's share price by initiating
the accusations that the generics manufacturer falsified data to
The rumours of a marriage between Japanese drugmakers Sankyo and
Daiichi Pharmaceutical were confirmed on Friday, when the two
companies officially announced their intention to merge in a stock
deal valued at around Y 813.0 billion...